Market Cap 102.95M
Revenue (ttm) 107.88M
Net Income (ttm) -33.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.07%
Debt to Equity Ratio -6.30
Volume 179,100
Avg Vol 169,672
Day's Range N/A - N/A
Shares Out 49.50M
Stochastic %K 6%
Beta 1.73
Analysts Strong Sell
Price Target $7.75

Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 259 5644
Address:
CAP Business Center, Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts, Herstal, Belgium
BillionerOfKing
BillionerOfKing Apr. 27 at 11:09 PM
$MDXH Current Stock Price: $2.03
0 · Reply
ThebookofEli
ThebookofEli Apr. 14 at 5:52 PM
$MDXH swinging some from here
0 · Reply
Lorb1
Lorb1 Apr. 8 at 6:17 PM
$MDXH This stock feels undervalued
0 · Reply
PaulLaurent
PaulLaurent Apr. 8 at 5:56 AM
🚀📈 Top Gainers 📈🚀AH $JEM $WGRX $MDXH $MGN $HCAI
0 · Reply
topstockalerts
topstockalerts Apr. 8 at 1:04 AM
After Hours Top Gainers PT2 $OSCG $CRMU $MDXH $MYSZ $FGNX
0 · Reply
UngenauOrange
UngenauOrange Apr. 5 at 4:38 PM
$MDXH @thecontracap @nbix16 @slick3333 There is a detail in the q4 press release about the fair value adjustment of 2,178m. It sais "1) Primarily related to GPS and ExoDx contingent considerations, option to pay Bio-Techne and Exact Sciences earnout in shares, and prepayment right of the OrbiMed loan" So the earnout payments not only got stretched out but also allow for payment in stock now. On the one hand it reduces that debt risk to the company but on the others we may face dilution which makes me agree with @nbix16 about ATM usage even more. Can anybody contribute to what this means? I'm not sure I fully understand.
0 · Reply
thecontracap
thecontracap Apr. 3 at 6:11 PM
$MDXH painful decline last 2 weeks, no doubt. I think mismanagement of expectations and technicals vs anything truly fundamental. I expect 25mm EBITDA in 27 and 35+ in 2028. Within 12 months, if we are tracking there, this should trade 10-15x 28 EBITDA conservatively. 350mm- 500mm EV. 120mm net debt. 230mm-380mm mkt cap. /55mm shares $4-7/sh. Best guess is they look to sell at that point. Michael is 63 and looking for the finish line. 3x rev very reasonable. 600mm EV. 480mm mkt cap. $8.75/sh. Annoyed I got run over on my large $3 purchase a couple weeks ago, but I’m looking to add down here. Talking to Michael on 4/6.
2 · Reply
UngenauOrange
UngenauOrange Mar. 30 at 6:27 PM
$MDXH Jesus. I may have to buy more :(
0 · Reply
nbix16
nbix16 Mar. 25 at 7:19 PM
$MDXH remain extremely bullish on the stock but I hope this arrogant ass McGarrity has learned why you should tap an ATM when the stock has rocketed 100% and you know you'll need cash at some point. Such arrogance it's baffling
0 · Reply
slick3333
slick3333 Mar. 21 at 5:55 AM
$MDXH we break below 3 next week sigh…..down the dumps we go again!
0 · Reply
Latest News on MDXH
MDxHealth Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 2 months ago

MDxHealth Earnings Call Transcript: Q4 2025


MDxHealth Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 6 months ago

MDxHealth Earnings Call Transcript: Q3 2025


Angle PLC Announces Strategy Update

Oct 8, 2025, 2:00 AM EDT - 7 months ago

Angle PLC Announces Strategy Update


MDxHealth Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 9 months ago

MDxHealth Earnings Call Transcript: Q2 2025


MDxHealth Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

MDxHealth Earnings Call Transcript: Q1 2025


MDxHealth Reports Q1-2025 Results

May 14, 2025, 4:00 PM EDT - 1 year ago

MDxHealth Reports Q1-2025 Results


MDxHealth Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MDxHealth Earnings Call Transcript: Q4 2024


MDxHealth Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

MDxHealth Earnings Call Transcript: Q3 2024


MDxHealth Announces Pricing of Offering of Ordinary Shares

Sep 25, 2024, 9:31 PM EDT - 1 year ago

MDxHealth Announces Pricing of Offering of Ordinary Shares


MDxHealth Announces Launch of Offering of Ordinary Shares

Sep 25, 2024, 4:05 PM EDT - 1 year ago

MDxHealth Announces Launch of Offering of Ordinary Shares


MDxHealth Earnings Call Transcript: Q2 2024

Aug 21, 2024, 4:30 PM EDT - 1 year ago

MDxHealth Earnings Call Transcript: Q2 2024


MDxHealth Reports Q2 and Half Year 2024 Results

Aug 21, 2024, 4:00 PM EDT - 1 year ago

MDxHealth Reports Q2 and Half Year 2024 Results


Mdxhealth Appoints Sanford J. Siegel, M.D.

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Mdxhealth Appoints Sanford J. Siegel, M.D.


Mdxhealth to Present at Upcoming Investor Conferences

May 15, 2024, 4:00 PM EDT - 2 years ago

Mdxhealth to Present at Upcoming Investor Conferences


MDxHealth Earnings Call Transcript: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

MDxHealth Earnings Call Transcript: Q1 2024


MDxHealth Earnings Call Transcript: Q4 2023

Mar 6, 2024, 4:30 PM EST - 2 years ago

MDxHealth Earnings Call Transcript: Q4 2023


Mdxhealth Announces Resignation of Board Member

Feb 16, 2024, 8:45 AM EST - 2 years ago

Mdxhealth Announces Resignation of Board Member


MDxHealth Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:30 PM EST - 2 years ago

MDxHealth Earnings Call Transcript: Q3 2023


Mdxhealth's New Share Capital Amount and New Number of Shares

Oct 20, 2023, 4:00 PM EDT - 2 years ago

Mdxhealth's New Share Capital Amount and New Number of Shares


MDxHealth Reports Preliminary Q3-2023 Revenues

Oct 9, 2023, 4:00 PM EDT - 2 years ago

MDxHealth Reports Preliminary Q3-2023 Revenues


MDxHealth Reports Q2 and Half Year 2023 Results

Aug 23, 2023, 4:00 PM EDT - 2 years ago

MDxHealth Reports Q2 and Half Year 2023 Results


MDxHealth Earnings Call Transcript: Q1 2023

May 15, 2023, 4:30 PM EDT - 3 years ago

MDxHealth Earnings Call Transcript: Q1 2023


MDxHealth Reports Q1-2023 Results

May 15, 2023, 4:00 PM EDT - 3 years ago

MDxHealth Reports Q1-2023 Results


MDxHealth Shareholder Transparency Declaration

Apr 7, 2023, 4:30 PM EDT - 3 years ago

MDxHealth Shareholder Transparency Declaration


MDxHealth Earnings Call Transcript: Q4 2022

Mar 8, 2023, 4:30 PM EST - 3 years ago

MDxHealth Earnings Call Transcript: Q4 2022


MDxHealth Announces Exercise of Option

Mar 6, 2023, 5:34 PM EST - 3 years ago

MDxHealth Announces Exercise of Option


MDxHealth Shareholder Transparency Declarations

Mar 3, 2023, 4:30 PM EST - 3 years ago

MDxHealth Shareholder Transparency Declarations


MDxHealth Earnings Call Transcript: Q2 2022

Aug 2, 2022, 4:30 PM EDT - 4 years ago

MDxHealth Earnings Call Transcript: Q2 2022


MDxHealth Earnings Call Transcript: Q4 2021

Mar 2, 2022, 4:30 PM EST - 4 years ago

MDxHealth Earnings Call Transcript: Q4 2021


MDxHealth Earnings Call Transcript: Q2 2021

Aug 26, 2021, 1:00 PM EDT - 5 years ago

MDxHealth Earnings Call Transcript: Q2 2021


BillionerOfKing
BillionerOfKing Apr. 27 at 11:09 PM
$MDXH Current Stock Price: $2.03
0 · Reply
ThebookofEli
ThebookofEli Apr. 14 at 5:52 PM
$MDXH swinging some from here
0 · Reply
Lorb1
Lorb1 Apr. 8 at 6:17 PM
$MDXH This stock feels undervalued
0 · Reply
PaulLaurent
PaulLaurent Apr. 8 at 5:56 AM
🚀📈 Top Gainers 📈🚀AH $JEM $WGRX $MDXH $MGN $HCAI
0 · Reply
topstockalerts
topstockalerts Apr. 8 at 1:04 AM
After Hours Top Gainers PT2 $OSCG $CRMU $MDXH $MYSZ $FGNX
0 · Reply
UngenauOrange
UngenauOrange Apr. 5 at 4:38 PM
$MDXH @thecontracap @nbix16 @slick3333 There is a detail in the q4 press release about the fair value adjustment of 2,178m. It sais "1) Primarily related to GPS and ExoDx contingent considerations, option to pay Bio-Techne and Exact Sciences earnout in shares, and prepayment right of the OrbiMed loan" So the earnout payments not only got stretched out but also allow for payment in stock now. On the one hand it reduces that debt risk to the company but on the others we may face dilution which makes me agree with @nbix16 about ATM usage even more. Can anybody contribute to what this means? I'm not sure I fully understand.
0 · Reply
thecontracap
thecontracap Apr. 3 at 6:11 PM
$MDXH painful decline last 2 weeks, no doubt. I think mismanagement of expectations and technicals vs anything truly fundamental. I expect 25mm EBITDA in 27 and 35+ in 2028. Within 12 months, if we are tracking there, this should trade 10-15x 28 EBITDA conservatively. 350mm- 500mm EV. 120mm net debt. 230mm-380mm mkt cap. /55mm shares $4-7/sh. Best guess is they look to sell at that point. Michael is 63 and looking for the finish line. 3x rev very reasonable. 600mm EV. 480mm mkt cap. $8.75/sh. Annoyed I got run over on my large $3 purchase a couple weeks ago, but I’m looking to add down here. Talking to Michael on 4/6.
2 · Reply
UngenauOrange
UngenauOrange Mar. 30 at 6:27 PM
$MDXH Jesus. I may have to buy more :(
0 · Reply
nbix16
nbix16 Mar. 25 at 7:19 PM
$MDXH remain extremely bullish on the stock but I hope this arrogant ass McGarrity has learned why you should tap an ATM when the stock has rocketed 100% and you know you'll need cash at some point. Such arrogance it's baffling
0 · Reply
slick3333
slick3333 Mar. 21 at 5:55 AM
$MDXH we break below 3 next week sigh…..down the dumps we go again!
0 · Reply
slick3333
slick3333 Mar. 13 at 3:38 AM
$MDXH sigh this one is a slow painful death …two resistance level left 3.12 and 3 and then comes the death spiral
0 · Reply
slick3333
slick3333 Mar. 4 at 12:53 AM
$MDXH looks really bad and we may hit low 2s with mediocre sales and increasing losses ….market only cares about guidance not slow movers that can produce somewhat ok revenue
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 26 at 10:14 PM
$MDXH Q4 '25 Earnings Results & Recap MDxHealth maintains its 2026 revenue guidance of $137M, expecting 27-30% growth. MDxHealth also confirms its view of driving progress toward a 10% adjusted EBITDA margin run rate exiting 2026.
0 · Reply
slick3333
slick3333 Feb. 26 at 9:12 PM
$MDXH dang as usual not the a fantabulous earning report and dump
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 3:13 PM
$MDXH RSI: 54.31, MACD: 0.0006 Vol: 0.10, MA20: 3.58, MA50: 3.50 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
FadeChaser
FadeChaser Feb. 18 at 9:18 AM
$MDXH Biotech where data consistency is critical; trust once lost is hard to regain.
0 · Reply
HiddenSentiment
HiddenSentiment Feb. 18 at 8:01 AM
$MDXH MDxHealth provides molecular diagnostics, facing test adoption dependent on clinician education and favorable insurance coverage [citation:historical].
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 12:14 AM
$MDXH Current Stock Price: $3.66
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 8:38 AM
$MDXH Brilliant piece that captures MDXH's situation perfectly. So if you want to update your understanding of MDXH or get to know MDXH better, this is essential reading. https://everyticker.com/quote/MDXH/analysis/mdxhealth-mdxh-unlocking-growth-in-urology-diagnostics-with-precision-technology
0 · Reply
Texasstockman1
Texasstockman1 Feb. 3 at 10:57 PM
$MDXH I like the way this company is shaping up. The stability is there, and the demand is real — especially with an aging population that increasingly needs these types of diagnostics. I’m looking for an entry soon, starting small and staying disciplined until they get past ER. Long-term, this space has meaningful upside if adoption continues.
0 · Reply
UngenauOrange
UngenauOrange Jan. 12 at 7:26 PM
$MDXH @slick3333 @nbix16 @thecontracap Two things. a) Regarding the tissue concerns. This reminds me that Veracyte had 27% growth for Decipher last quarter when mdxh was flat. They also said that they try to go more into the low risk patient market. That's where mdxh mostly is afaik. I planned to look into this but never did. Seems like it is a good time to do so now. Do you have insights into this yet? b) Do you guys plan to look into the study from the last press release? I will try to but not sure how to go about it yet. Would love if we could share results and compare notes here.
1 · Reply
slick3333
slick3333 Jan. 12 at 2:49 PM
$MDXH guess preliminary sales not good enough
2 · Reply